Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Lepu Biopharma (乐普生物科技) IPO: Sentiment Cooled Down

Lepu Biopharma (乐普生物科技) Pre-IPO: Differentiation Strategy for Intense Competition

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

China Health care / Quantitative Analysis

<ul>
<li>Lepu Biopharma raised HKD 804.2 million (USD 103m) from its global offering and will list on the Hong Kong Stock Exchange on Wednesday, Feb 23rd.</li>
<li>Despite its differentiation strategy, we think the company's debut performance will be mainly affected by the high share concentration, and poor sentiment in the sector.</li>
<li>In this note, we look at the updates since our last note and prior to debut.</li>
</ul>


Lepu Biopharma raised HKD 804.2 million (USD 103m) from its global offering and will list on the Hong Kong Stock Exchange on Wednesday, Feb 23rd.
Despite its differentiation strategy, we think the company's debut performance will be mainly affected by the high share concentration, and poor sentiment in the sector.
In this note, we look at the updates since our last note and prior to debut.


Lepu Biopharma (乐普生物科技) IPO Trading: High Share Concentration